学科主题 | 公共卫生 |
Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study | |
Yang, Li1; Christensen, Torsten2; Sun, Fengyu3; Chang, Jinghua3 | |
关键词 | Chinese setting cost-effectiveness cost-utility insulin detemir |
刊名 | VALUE IN HEALTH
![]() |
2012 | |
DOI | 10.1016/j.jval.2011.11.018 |
卷 | suppl.S期:1页:S56-S59 |
收录类别 | SCI ; SSCI |
文章类型 | Article |
WOS标题词 | Social Sciences ; Science & Technology |
类目[WOS] | Economics ; Health Care Sciences & Services ; Health Policy & Services |
研究领域[WOS] | Business & Economics ; Health Care Sciences & Services |
关键词[WOS] | THERAPY CONVERSION ; MELLITUS ; OUTCOMES ; ASPART |
英文摘要 | Objectives: To evaluate the long-term cost-effectiveness of switching from insulin glargine (IGla) to insulin detemir (IDet) in patients with type 2 diabetes in the setting of Chinese secondary and tertiary hospitals. Methods: A published and validated computer simulation model of diabetes (the Center for Outcomes Research model) was used to make the long-term (30 years) projection of health economic outcomes. Patient demographic information and clinical end points were derived from a subgroup analysis of the Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Variability Evaluation (PREDICTIVE) study. Baseline risk factors and racial characteristic data were obtained from Chinese cohort studies. The diabetes management and complications costs were obtained from Chinese published data and adjusted to 2010 values by using the Chinese consumer price index. An annual discounting rate of 3% was used for both health and cost outcomes, and one-way sensitivities analysis was performed, which illustrated that the results were robust. Results: Conversion to IDet from IGla was projected to improve patient life expectancy by 0.06 year and 0.48 quality-adjusted life-years. Drug costs and management costs of diabetes mellitus were increased by US$368 (US$17,466 vs. US$17,097) and US$31 (US$5464 vs. US$5433), respectively. However, the costs of complications, including cerebrovascular disease, renal complications, ulcer/amputation/neuropathy, eye complications, and hypoglycemia events, were reduced by US$ 819 (US$21,294 vs. US$22,114), resulting in a total direct medical cost saving of US$420 when converting to IDet. Conclusions: Conversion to IDet from an IGla regimen improved life expectancy and was a cost-saving treatment approach in a Chinese setting. |
语种 | 英语 |
WOS记录号 | WOS:000299317000010 |
Citation statistics | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.bjmu.edu.cn/handle/400002259/61629 |
Collection | 北京大学公共卫生学院 |
作者单位 | 1.Novo Nordisk AS, Virum, Denmark 2.Novo Nordisk China Pharmaceut Co Ltd, Beijing, Peoples R China 3.Peking Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Beijing 100191, Peoples R China |
Recommended Citation GB/T 7714 | Yang, Li,Christensen, Torsten,Sun, Fengyu,et al. Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study[J]. VALUE IN HEALTH,2012,suppl.S(1):S56-S59. |
APA | Yang, Li,Christensen, Torsten,Sun, Fengyu,&Chang, Jinghua.(2012).Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study.VALUE IN HEALTH,suppl.S(1),S56-S59. |
MLA | Yang, Li,et al."Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study".VALUE IN HEALTH suppl.S.1(2012):S56-S59. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment